HNGE vs OGN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HNGE presents a stark contrast between operational growth and financial health, anchored by a weak Piotroski F-Score of 2/9. While the company exhibits strong top-line revenue growth (45.6%) and impressive gross margins (79.83%), it suffers from severe net profitability issues and a highly inflated Price-to-Book ratio of 19.95. The bullish analyst consensus is heavily contradicted by aggressive insider selling totaling $35.15M. Overall, the company is in a high-growth phase but lacks the fundamental stability required for a bullish rating.
OGN presents a high-risk profile characterized by a Piotroski F-Score of 4/9 (Stable) and a critical Debt/Equity ratio of 11.70. While the stock has experienced a massive speculative rally over the last 60 days, the current price of $13.25 is significantly decoupled from its Graham Number ($7.82) and Intrinsic Value ($6.58). Fundamental deterioration is evident in the -5.30% revenue growth and -30.4% YoY EPS growth, suggesting the recent price surge is not supported by operational performance.
Compare Another Pair
Related Comparisons
HNGE vs OGN: Head-to-Head Comparison
This page compares Hinge Health, Inc. (HNGE) and Organon & Co. (OGN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.